CliffBio
small molecule

XTAMPZA ER

OXYCODONE

Loss of exclusivitySeptember 2036latest FDA-listed patent expiry
CompanyCollegium Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameXTAMPZA ER
Active ingredientOXYCODONE
Strength18MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2016
Marketing statusRX

Listed patents

PatentExpiresType
9968598September 2036product
10646485September 2036product
10188644September 2036product
9737530September 2036product
9682075December 2030product
10004729December 2030product
10668060December 2030product
7771707October 2028product

More from Collegium Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XTAMPZA ER patent cliff — loss of exclusivity September 2036 | CliffBio